<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:10pt Arial, sans-serif; }
 .font2 { font:11pt Arial, sans-serif; }
 .font3 { font:17pt Arial, sans-serif; }
 .font4 { font:10pt Times New Roman, serif; }
 .font5 { font:15pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font5">JPMorgan</span></p>
<p><span class="font0" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.2hao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.2hao@jpmorgan.com</span></a></p><a name="caption1"></a>
<h4><a name="bookmark0"></a><span class="font3"><a name="bookmark1"></a>Investment Thesis, Valuation and Risks</span></h4>
<p><span class="font2" style="font-weight:bold;">Fosun Pharmaceutical - H </span><span class="font1" style="font-style:italic;">(Overweight; Price Target: HK$28.00)</span></p>
<p><a name="bookmark2"></a><span class="font4" style="font-weight:bold;"><a name="bookmark3"></a>Investment Thesis</span></p>
<p><span class="font4">Fosun is a leading Chinese healthcare company with business operations covering most of the important segments in the healthcare industry value chain. The Group has expanded rapidly through organic growth, M&amp;A and strategic investments. The company owns about 30% of Sinopharm, which forms part of Fosun’s core valuation. It has recently vastly expanded its manufacturing operations through aggressive acquisitions, including Jinzhou Aohong, which produces Aodejin, a top-5 bestselling prescription drug in China. It has also aggressively been amassing hospital sendees assets, which allows the company to participate in a potentially very lucrative space.</span></p>
<p><a name="bookmark4"></a><span class="font4" style="font-weight:bold;"><a name="bookmark5"></a>Valuation</span></p>
<p><span class="font4">Our Dec-17 price target of HK$28.0 is based on a DCF valuation which assumes a market premium of 6.0% and a risk-free rate of 4.2% (yield on ten-year government notes in China). We assume a beta of 1.0 based on regression analysis performed by Bloomberg. Accordingly, we assume a WACC of 8.3%. We estimate free cash flow for Fosun until 2020 and assume a terminal growth rate of 4.0%.</span></p>
<p><a name="bookmark6"></a><span class="font4" style="font-weight:bold;"><a name="bookmark7"></a>Risks to Rating and Price Target</span></p>
<p><span class="font4">Key risks to our rating and PT include 1) unfavorable government policies on prices of healthcare products and sendees, 2) failure to gain from any future M&amp;A transactions in terms of yield synergies and growth, 3) unexpected delays in the approval and launch of new products, and 5) penetrating private healthcare sendees and realizing target returns proving exceedingly difficult.</span></p>
<p><span class="font0" style="font-weight:bold;">31</span></p>
</body>
</html>